Two Sigma Advisers’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Two Sigma Advisers’s Portfolio EVLO Stock Details EVLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,315	Closed	-$55K	–	2795
2022 Q2	$55K	Sell	1,315 -4,200	-76%	-$195K	﹤0.01%	2466
2022 Q1	$374K	Sell	5,515 -10	-0.2%	-$832	﹤0.01%	2126
2021 Q4	$671K	Sell	5,525 -1,505	-21%	-$254K	﹤0.01%	1764
2021 Q3	$990K	Buy	7,030 +1,005	+17%	+$199K	﹤0.01%	1627
2021 Q2	$1.66M	Buy	6,025 +2,715	+82%	+$685K	﹤0.01%	1391
2021 Q1	$708K	Buy	+3,310	New	+$915K	﹤0.01%	1842

Other funds holding EVLO

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers's EVLO Position: Q3 2022 in Review

Two Sigma Advisers sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q3 2022, closing a stake of 1,315 shares — an estimated $55K sold.

Two Sigma Advisers first reported a position in EVLO in Q1 2021 and held it in 6 quarters. The position peaked at $1.66M in Q2 2021. 41 funds tracked by Wall St. Rank hold EVLO as of Q3 2022.

Two Sigma Advisers reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Two Sigma Advisers sold 1,315 Evelo Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $55K.
Two Sigma Advisers first reported a position in Evelo Biosciences, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
Two Sigma Advisers's Evelo Biosciences, Inc. Common Stock position peaked at $1.66M in Q2 2021.
41 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q3 2022.

Based on Two Sigma Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.